Novartis Investigative Site

South Brisbane, Queensland 4101

0 studies enrolling now · 15 studies all time

What they study most

Breast Cancer, Carcinoid Tumor, Cutaneous T-Cell Lymphoma, HER2/Neu Over-expressing Locally Advanced Breast Cancer, Malignant Carcinoid Syndrome, Melanoma, Metastatic Breast Cancer, Metastatic Hormone Refractory Prostate Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma, Neoplasms, Breast, Non-Small Cell Lung Cancer

Studies at this site

• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Running, not enrolling
• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients — Completed
• Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD — Completed
• Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma — Completed
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma — Completed
• Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Completed
• Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. — Completed
• Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer — Completed
• Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor — Completed
• Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer — Completed
• Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer — Completed
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING
• Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma — Completed
• Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed